| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | AVIL |
| Uniprot No | O75366 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-819aa |
| 氨基酸序列 | MPLTSAFRAVDNDPGIIVWRIEKMELALVPVSAHGNFYEGDCYVILSTRRVASLLSQDIHFWIGKDSSQDEQSCAAIYTTQLDDYLGGSPVQHREVQYHESDTFRGYFKQGIIYKQGGVASGMKHVETNTYDVKRLLHVKGKRNIRATEVEMSWDSFNRGDVFLLDLGKVIIQWNGPESNSGERLKAMLLAKDIRDRERGGRAKIGVIEGDKEAASPELMKVLQDTLGRRSIIKPTVPDEIIDQKQKSTIMLYHISDSAGQLAVTEVATRPLVQDLLNHDDCYILDQSGTKIYVWKGKGATKAEKQAAMSKALGFIKMKSYPSSTNVETVNDGAESAMFKQLFQKWSVKDQTMGLGKTFSIGKIAKVFQDKFDVTLLHTKPEVAAQERMVDDGNGKVEVWRIENLELVPVEYQWYGFFYGGDCYLVLYTYEVNGKPHHILYIWQGRHASQDELAASAYQAVEVDRQFDGAAVQVRVRMGTEPRHFMAIFKGKLVIFEGGTSRKGNAEPDPPVRLFQIHGNDKSNTKAVEVPAFASSLNSNDVFLLRTQAEHYLWYGKGSSGDERAMAKELASLLCDGSENTVAEGQEPAEFWDLLGGKTPYANDKRLQQEILDVQSRLFECSNKTGQFVVTEITDFTQDDLNPTDVMLLDTWDQVFLWIGAEANATEKESALATAQQYLHTHPSGRDPDTPILIIKQGFEPPIFTGWFLAWDPNIWSAGKTYEQLKEELGDAAAIMRITADMKNATLSLNSNDSEPKYYPIAVLLKNQNQELPEDVNPAKKENYLSEQDFVSVFGITRGQFAALPGWKQLQMKKEKGLF |
| 预测分子量 | 92 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于AVIL(Advillin)重组蛋白的模拟参考文献示例(注：部分内容为假设性概括，建议通过学术数据库核实具体文献)：
1. **文献名称**: "Advillin promotes tumor metastasis through cytoskeletal remodeling in pancreatic cancer"
**作者**: Li, X. et al.
**摘要**: 本研究揭示了AVIL重组蛋白通过调控肌动蛋白细胞骨架重组促进胰腺癌细胞侵袭转移的分子机制，为靶向AVIL的癌症治疗提供依据。
2. **文献名称**: "Expression and purification of recombinant Advillin in E. coli for functional studies"
**作者**: Zhang, Y. & Wang, H.
**摘要**: 报道了一种高效表达AVIL重组蛋白的大肠杆菌系统，通过亲和层析纯化获得高活性蛋白，并验证其与F-actin的结合能力。
3. **文献名称**: "Advillin interacts with TRPV4 to mediate mechanical nociception in sensory neurons"
**作者**: Chen, Z. et al.
**摘要**: 利用重组AVIL蛋白进行互作实验，发现其与TRPV4离子通道共同参与机械性疼痛信号传导，为神经病理性疼痛机制研究提供新方向。
4. **文献名称**: "Structural insights into the actin-binding domains of Advillin by cryo-EM"
**作者**: Tanaka, K. et al.
**摘要**: 通过冷冻电镜解析AVIL重组蛋白的肌动蛋白结合结构域三维结构，阐明其调控细胞形态的动态机制。
**建议**：使用PubMed、Web of Science或Google Scholar搜索关键词"recombinant Advillin"或"AVIL protein"获取最新文献，并优先选择近5年发表的论文以跟踪前沿进展。
AVIL (Advillin) is a member of the gelsolin/villin family of actin-binding proteins, initially identified for its role in regulating cytoskeletal dynamics. It is expressed in neuronal tissues, mesenchymal cells, and certain cancers, where it modulates cell motility, invasion, and survival by interacting with actin filaments. AVIL gained attention in oncology after studies linked its overexpression to tumor progression, particularly in aggressive cancers like glioblastoma, neuroblastoma, and sarcomas. Its oncogenic potential stems from its ability to stabilize actin networks, promote metastasis, and suppress apoptosis, making it a potential therapeutic target.
Recombinant AVIL proteins are engineered using expression systems (e.g., E. coli, mammalian cells) to produce purified, functional forms for research and drug development. These proteins retain key domains, including conserved gelsolin-like repeats that mediate actin binding. Researchers utilize recombinant AVIL to study its biochemical interactions, screen inhibitory compounds, and generate antibodies. For instance, studies demonstrated that inhibiting AVIL with recombinant antibodies or CRISPR-mediated knockout reduces cancer cell proliferation in vitro and tumor growth in vivo.
The development of AVIL-targeted therapies, such as small-molecule inhibitors or biologics, is an active area of investigation. Recombinant AVIL also serves as a critical tool for elucidating its signaling pathways, including crosstalk with oncogenic drivers like MYC. Despite progress, challenges remain in understanding tissue-specific roles and optimizing delivery strategies for AVIL-based interventions. Overall, recombinant AVIL proteins bridge mechanistic insights and translational applications in cancer biology.
×
